Conformis Appoints Senior Vice President, Operations
Matthew Scott takes leadership on scaling operations to meet growing demand for Conformis’ patient-specific technology
Conformis, Inc., a privately held medical device company pioneering patient-specific orthopedic implants, announced today it has appointed orthopedic industry veteran Matthew Scott as the company’s Senior Vice President of Operations. Mr. Scott brings extensive operations experience to Conformis, including over a decade of medical device manufacturing and operations leadership with Zimmer Orthopedics and Zimmer Dental.
Mr. Scott was most recently the Director of Operations for Zimmer Dental, reporting to the President. At Zimmer Dental, he oversaw all aspects of the operation and managed the rapid growth of the dental implant manufacturing facilities during his tenure. Prior to Zimmer Dental, Mr. Scott held various roles at Zimmer Orthopedics, where he started as the production manager for the knee femoral business. His deep familiarity with the production technologies used in orthopedics led to leadership roles on teams responsible for lean process redesign, cost efficiencies, and technology transfer.
Mr. Scott was also responsible for helping establish a global network of manufacturing facilities to support the hip and knee implant business. He developed the business case for several overseas facilities, planned and executed the build out of the sites, and served as interim general manager of a new production facility in Ireland before moving to Zimmer Dental.
“We are extremely pleased to welcome Matthew to the senior team at Conformis,” said Philipp Lang, M.D., CEO of Conformis. “Conformis is building a next generation orthopedics company not just through innovative product design but via a fundamental rethink of the business model. Matthew’s leadership will be integral in scaling up manufacturing to keep up with growth, but also in reengineering our operations to take full advantage of the patient-specific, just-in-time nature of our approach.”
Conformis takes a unique approach to manufacturing compared with traditional off-the-shelf implants. Using advanced 3D design and manufacturing technology, Conformis creates customized implants and instruments for each patient based on their imaging data. The system is delivered as an efficient, single use kit just prior to the surgery, providing hospitals with opportunities for savings on inventory management, sterilization and operating room set up and turnover.
“Conformis’ high growth and unique business model creates a great environment where you have to deliver, but you also get a chance to be innovative,” said Matt. “I’m thrilled to be joining this team and to have an opportunity to work on such fundamental innovations in orthopedic manufacturing.”
For more information on Conformis visit conformis.com.
About Conformis, Inc.
Conformis, Inc. is a privately-held medical device company that is pioneering a patient-specific approach to orthopedic implants and instrumentation. Its proprietary intellectual property includes more than 375 patents and patent applications in the areas of image processing, implant design, surgical techniques, instrumentation, and manufacturing across multiple joints. Conformis’ award winning solutions, the iUni® G2, iDuo® G2 and iTotal® G2, offer a personalized approach to knee replacement with unique benefits over traditional off-the-shelf implants. All devices have been cleared by the U.S. FDA for marketing in the US and CE Marked in Europe. Follow @Conformis and become a fan on Facebook.
New Implant Technology, A New Twist On Knee Replacement
The Cape Cod Chronicle: ConforMIS, is breaking new ground in the field of knee replacements by offering something never seen before: customized knee implants designed and manufactured for each individual patient, with no two quite alike.
Four-Year Data from the UK National Joint Registry Highlights High Survivorship in Patients Treated with the Conformis iTotal CR
Data Shows a Low Cumulative Percent Revision of 0.5% for Conformis Patients vs 1.9% for all Total Knee Replacement Patients